Time-Cap Labs, Inc. has been acquired by Marksans Pharma Ltd.
The founder and owner of Time-Cap Labs, Inc. has sold the company to Marksans Pharma Limited for an undisclosed consideration.
Founded in 1978 and based in Farmingdale, New York, Time-Cap Labs, Inc. manufactures and supplies generic pharmaceuticals and over-the-counter drugs. The company specializes in delayed and sustained release dosages. It offers various formulations, including analgesics, laxatives, dietary supplements, cough and cold medications, prescription drugs, antacids, and other products. The company offers its products to large and small wholesalers and distributors.
Marksans Pharma Limited, together with its subsidiaries, is engaged in the research, manufacture, and marketing of generic pharmaceutical formulations worldwide. Its product portfolio covers primary therapeutic segments of CVS, analgesics, decongestants, gastrointestinal, cardiovascular, anti-diabetics, central nervous system, oncology, anti-allergic drugs, and others. It also manufactures and distributes over-the-counter pharmaceutical products in the areas of cough and cold remedies, galenicals, vitamins, palliative and healthcare items, oils, antiseptics, and disinfectants; and offers contract research and manufacturing services to global pharmaceutical companies. Marksans Pharma Limited is headquartered in Mumbai, India.
One of Oaklins' teams in the USA served as the exclusive financial advisor to the seller in this transaction.
Talk to the deal team
Paul R. Smolevitz
Oaklins TM Capital
James McLaren
Oaklins TM Capital
Related deals
Afric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn moreBayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn more